Dr. Defne Audrey Amado, MD, PhD

Dr. Amado practices at Pennsylvania Hospital in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Amado's NPI, 1407149602, was assigned on May 20, 2011. Dr. Amado graduated from Perelman School of Med at the University of Pennsylvania in 2011. Dr. Amado holds Pennsylvania license MD454452.

Dr. Amado's primary practice is Pennsylvania Hospital, at 800 Spruce Street, Philadelphia, PA 19107 in Philadelphia County. The practice phone is (215) 829-3000.

Dr. Amado's primary practice is Pennsylvania Hospital in Philadelphia, Pennsylvania, part of University of Pennsylvania. Dr. Amado is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Amado to 1 more hospital and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amado practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Amado's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Amado is licensed in Pennsylvania.

CMS data shows 98 Medicare services from Dr. Amado across 3 procedure codes in 2024, for 57 Medicare patients. Medicare paid $7,472 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 57 Medicare patients who saw Dr. Amado in 2024. The largest group is 75 to 84, with 20 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amado's median patient age at 63, with 57% women.

In 2024, Dr. Amado wrote 366 Medicare Part D claims for 41 patients. 72% of them were for generic drugs. CMS names the drug for 252 of them, across 9 drugs with 11 or more claims each, at $1,111,469 in total drug cost. In 2023, CMS named 229 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Amado for performance year 2024, reported as part of a group. Dr. Amado accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 24 papers to Dr. Amado, published from 2013 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Amyotrophic Lateral Sclerosis, Brain and Frontotemporal Dementia. Dr. Amado has published most often in medRxiv. Dr. Amado's most frequent co-authors are Lauren B. Elman, MD, Colin C. Quinn, MD and Michael Baer.

CMS Open Payments shows 4 general payments to Dr. Amado from 3 drug and device companies from 2016 to 2023. Speaker and faculty fees make up the largest share, 59% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $4,147.

Dr. Amado graduated from Perelman School of Med at the University of Pennsylvania in 2011.